Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics Holdings, Inc. (NYSE American: SENS) announced that EmblemHealth is now covering the Eversense® Continuous Glucose Monitoring (CGM) System, effective immediately, expanding access to around 2.9 million residents in New York, New Jersey, and Connecticut. This addition highlights the growing recognition among payers of CGM as a standard care for insulin-dependent diabetes management. The Eversense system features an implantable sensor and smart transmitter that enhances glucose monitoring. Improved coverage may aid in achieving better health outcomes for patients.
Senseonics Holdings, Inc. (NYSE American: SENS) has announced a registered direct offering of 40,000,000 shares of common stock at $1.25 per share, expected to raise $50.0 million before expenses. The offering is managed by H.C. Wainwright & Co. and is slated to close on or about January 21, 2021. The net proceeds will be allocated for general corporate purposes. The shares are being offered under a shelf registration statement filed with the SEC, ensuring compliance with regulatory requirements.
Senseonics Holdings, Inc. (SENS) has granted equity to four new non-executive employees under its 2019 Inducement Plan, totaling 22,000 stock options and 280,000 restricted stock units. The stock options have an exercise price of $0.95 per share, correlating with the closing price on January 5, 2021. Vesting occurs over four years, contingent on continued employment. This move aims to strengthen Senseonics' workforce as it seeks to expand its Eversense continuous glucose monitoring system for diabetes patients in the U.S. and internationally.
Senseonics Holdings, Inc. (NYSE American: SENS) announced key financial and operational updates, projecting fourth-quarter 2020 net revenue of approximately $3.5 million, up from earlier estimates of $2.5 million. Full-year 2021 revenue is expected between $12 and $15 million. The FDA has delayed the marketing review of the Eversense 180-day product by at least 60 days due to resource reallocation for COVID-19. Notably, Eversense received inclusion in the 2021 CMS Physician Fee Schedule, improving access for Medicare patients as the company transitions distribution to Ascensia.